Demographic and laboratory baseline characteristics of <i>S. haematobium</i>-infected children treated with mefloquine-artesunate plus praziquantel, mefloquine plus praziquantel, and praziquantel.

<p>* 18 malaria slides.</p><p>** <50 eggs/10 ml of urine.</p

Number of specific mild and moderate adverse events, stratified by treatment, as assessed at different time points posttreatment.

a<p>: 16 patients participated at adverse events examinations.</p><p>* significantly different from praziquantel (p<0.05) using Pearson's χ² test.</p

Number of children with adverse events among the three treatment arms, as assessed at different time points posttreatment.

<p>NA: not applicable.</p>a<p>: 16 patients participated at adverse events examinations.</p><p>* significantly different from praziquantel (p<0.05) using Pearson's χ² test.</p

Consort flowchart.

<p>Study enrollment, allocation, follow-up, and analysis.</p

Effect of artesunate-mefloquine plus praziquantel, mefloquine plus praziquantel, and praziquantel on <i>S. haematobium</i> and concomitant co-infections at the second treatment follow-up.

<p>Effect of artesunate-mefloquine plus praziquantel, mefloquine plus praziquantel, and praziquantel on <i>S. haematobium</i> and concomitant co-infections at the second treatment follow-up.</p

Flowchart showing study participation.

<p>Flowchart detailing study participation and adherence of preschool-aged children for submitting two stool and two urine samples for the diagnosis of <i>S. mansoni</i>, <i>S. haematobium</i>, and soil-transmitted helminths before and after administration of praziquantel in the two study villages in the Azaguié district, south Côte d'Ivoire, in August and September 2011.</p

Baseline prevalence of helminths according to diagnostic approach (<i>n</i> = 242).

<p>The study was carried out in Azaguié, south Côte d'Ivoire in August and September 2011. Duplicate Kato-Katz thick smears were prepared from each stool sample and a single POC-CCA cassette test was done on urine samples collected over two consecutive days. Infection intensities are based on thresholds put forth by WHO <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0002109#pntd.0002109-WHO1" target="_blank">[1]</a>. The POC-CCA test results were categorized as light (1+), moderate (2+), and heavy (3+).</p><p>CI, confidence interval; n.d., not defined; POC-CCA, point-of-care circulating cathodic antigen; t−, trace negative; t+, trace positive.</p

Number of preschool-aged children falling in each POC-CCA test score before and after treatment.

<p><i>n</i> = 86, Day 1: first day of urine collection, Day 2: second day of urine collection.</p>a<p>Combined POC-CCA cassette test (days 1 and 2), as defined in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0002109#pntd-0002109-t001" target="_blank">Table 1</a>.</p>b<p>The higher POC-CCA cassette test score from either day 1 or day 2 was considered as final score.</p

Agreement between Kato-Katz technique and POC-CCA cassette test for the diagnosis of <i>S. mansoni</i>.

<p>The study was carried out in Azaguié, south Côte d'Ivoire in August and September 2011.</p>*<p>κ indicating kappa; κ<0, no agreement; κ = 0–0.2, poor agreement; κ = 0.21–0.4, fair agreement; κ = 0.41–0.6, moderate agreement; κ = 0.61–0.8, substantial agreement; κ = 0.81–1.0, almost perfect agreement <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0002109#pntd.0002109-Landis1" target="_blank">[35]</a>.</p><p>t−, trace negative; t+, trace positive.</p

Comparison of test requirements of POC-CCA cassette test and Kato-Katz technique.

<p>No detailed requirements of each test are mentioned in this table, but the main requirements of each test are emphasized.</p